Amanta Healthcare

AMANTA · NSE

— · —

₹150.27

Closing price — 16 Jun 2026

Market cap ₹696 Cr · EPS ₹0.74

Valuation

Blended fair value using DCF and peer comparison methods.

See if Amanta Healthcare is undervalued

Unlock intrinsic value for 4,800+ Indian stocks — free.

Company in heavy investment phase. DCF based on operating cash flow. Peer comparison weighted more heavily.

The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.

Peer comparison

How this company stacks up against sector peers on valuation and quality metrics.

Healthcare · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Amanta Healthcare AMANTA · you	₹696 Cr	35.4×	2.7×	13.4×	6.8%	5.2%	3.5%
Sector median	—	41.8×	4.1×	31.9×	12.0%	6.4%	3.6%
Innova Captab Limited INNOVACAP	₹5,064 Cr	42.5×	5.5×	22.9×	12.9%	8.6%	20.7%
IOL Chemicals and Pharmaceuticals Limited IOLCP	₹4,853 Cr	28.9×	2.9×	—	10.1%	0.1%	—
Morepen Laboratories Limited MOREPENLAB	₹4,776 Cr	46.8×	3.6×	32.0×	7.6%	5.3%	8.4%
Gujarat Themis Biosyn Limited GUJTHEM	₹4,480 Cr	81.1×	13.2×	61.4×	16.2%	28.2%	3.6%
Aarti Drugs Limited AARTIDRUGS	₹3,901 Cr	20.0×	2.5×	13.4×	12.6%	7.6%	-1.9%
Unichem Laboratories Limited UNICHEMLAB	₹3,793 Cr	22.8×	1.6×	—	7.0%	0.0%	—
Novartis India Limited NOVARTIND	₹3,671 Cr	41.0×	4.7×	31.9×	11.4%	26.3%	-2.2%
Kwality Pharmaceuticals Limited KPL	₹3,574 Cr	44.1×	14.7×	—	33.4%	0.2%	—

Peer comparison verdict

Amanta trades at a discount to sector peers on P/E (35.4× vs median 41.8×). This may signal undervaluation — or reflect lower expected growth or higher perceived risk versus the peer group.

Business quality

Valuation

P/E ratio

35.4×

P/B ratio

—

EV/EBITDA

—

Price/Sales

—

Returns

ROE

6.8%

ROCE

9.2%

ROA

—

Growth

Revenue CAGR (3yr)

3.5%

EPS CAGR (3yr)

—

Efficiency

Asset turnover

—

FCF yield

-4.6%

Dividend yield

—

Liquidity & Solvency

Debt / Equity

0.74×

Debt / EBITDA

—

Interest coverage

1.9×

Current ratio

1.69×

Quick ratio

—

Financial health

Piotroski F-Score, Altman Z-Score, and key solvency ratios.

Financial health data is not yet available for this company.

Full financial data

Charts and annual statements for income, balance sheet and cash flow.

Income trend

Revenue, profit and margin trends over time.

Revenue

Net profit

Operating margin

Net margin

Revenue

₹288 Cr

Net profit

₹15 Cr

Operating margin

—

Net margin

5.2%

Revenue and net profit in ₹ Crores (left axis). Margins % on right axis.

Cash flow

Where cash comes from and where it goes.

Operating CFInvesting CFFinancing CFFree cash flow

Operating CF — Cash earned from running the business. The core engine of financial health.

Investing CF — Cash spent on assets and equipment. Negative is normal — it means the company is investing in growth.

Financing CF — Cash from borrowing or repaying loans and dividends. Negative means debt is being repaid.

Free cash flow — Operating CF minus capex. Cash left after keeping the business running. Positive and growing is ideal.

Operating CF

₹48.45 Cr

Investing CF

₹0 Cr

Financing CF

₹0 Cr

Free cash flow

-₹31.74 Cr

Balance sheet

Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.

How the company is funded — equity is owners' money, debt is long-term borrowing, current liabilities are short-term obligations.

Equity

Debt

Current liabilities

Total assets

—

Total debt

₹162 Cr

Equity

₹220 Cr

Debt / Equity

0.74×

Numbers are illustrative — order-of-magnitude correct. For precise figures, refer to the company's annual report on BSE/NSE.

Shareholding pattern

Who owns this company and how that has changed.

What shareholding tells you: When promoters (founders/controlling shareholders) increase their stake, it usually signals confidence in the business. Rising FII (foreign funds) interest means international money is moving in. High promoter pledge is a risk — pledged shares can be force-sold if the stock price falls sharply.

Latest quarter

Promoter

63.8%

+0.1 pp QoQ

FII

0.4%

-0.4 pp QoQ

DII

12.9%

+0.0 pp QoQ

Retail

22.8%

Trend over time (%)

Quarterly data

Category	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Change (YoY)
Promoter	63.6%	63.6%	63.7%	63.8%	+0.2 ppvs oldest
FII (Foreign)	1.0%	1.1%	0.8%	0.4%	-0.6 ppvs oldest
DII (Domestic)	11.3%	11.2%	12.9%	12.9%	+1.6 ppvs oldest
Retail	24.1%	24.1%	22.6%	22.8%	-1.3 ppvs oldest

Signals from the trend

➡️

PromoterStable — no notable buying or selling

📉

FIINet sellers (0.6pp) — foreign institutional interest is declining

📈

DIINet buyers (+1.6pp) — domestic funds are accumulating

Mixed signals — DII buying on the positive side, but FII outflows adds uncertainty.

pp = percentage points. FII = Foreign Institutional Investors. DII = Domestic Institutional Investors (MFs, insurance). Data sourced from NSE/BSE filings. Verify on BSE/NSE before any investment decision.